The space of the migraine pipeline is filled to the brim with novel therapies

Los Angeles, USA, September 16, 2021 (GLOBE NEWSWIRE) – The migraine pipeline space is brimming with new new therapies with over 30 pharmaceutical companies working in the domain | DelveInsight

The migraine pipeline landscape is robust and is being driven by new therapies that hold promise to change the migraine treatment regimen in the years to come.

DelveInsights Insights into the migraine pipeline The report provides comprehensive coverage of emerging migraine therapies at various stages of clinical trials from preclinical to late end-stage, along with dormant, inactive, and discontinued drugs.

The Migraine Pipeline Report provides a complete overview of ongoing clinical trials, partnerships in the domain, recent space events and opportunities, and hurdles in the migraine pipeline domain.

Some of the key highlights from the Migraine pipeline Report:

  • The Migraine Pipeline Report offers a comprehensive analysis of 30+ Key player and 30+ Key therapies.
  • The migraine pipeline includes therapies at various stages of the clinical phase, such as: Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, AbbVie, Eli Lilly and Company, Allodynic Therapeutics, Trevena, AEON Biopharma, Sosei Heptares, Vaxxinity, Pulmatrix, Pear Therapeutics, BetterLife Pharma, and others, with many others expected to enter the migraine market in the next decade.
  • Some of the key companies working to strengthen the migraine pipeline are Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics, among other.
  • In June 2021, Sosei Group Corporation announced the start of a Phase I clinical trial of HTL0022562 (also known as BHV3100), a novel, low-molecular-weight CGRP receptor antagonist for the treatment of migraines. (NCT04941989)
  • In March 2021, AbbVie announced that the US FDA had approved a new drug application (NDA) for Atogepant for the preventive treatment of migraines. The NDA approval was obtained through data from a regulatory approval Phase III ADVANCE clinical study, a pivotal phase IIb / III study and a phase III long-term safety study.
  • In March 2021 Biohaven Pharmaceutical enrolled the first subject in the clinical phase II / III study with oral Zavegepant for the preventive treatment of migraines (NCT04804033).

Request a sample to learn about the emerging therapy that is expected to reach the maximum patient pool @ New therapies and prognoses for migraines

Migraine is a condition that causes severe, recurring headaches and other symptoms such as tingling sensations, flashing lights, strange noises, and blurred or lost vision. The condition has no cure; However, treatments are available, including over-the-counter (OTC) medications for pain relief.

For more information on new drugs, see Migraine pipeline analysis

Migraine pipeline drugs

drug society phase MoA RoA
Zavegepant Biohaven Pharma Phase III Calcitonin Gene-Related Peptide Receptor Antagonists Oral / intranasal
STS-101 Satsuma Pharmaceuticals Phase III Serotonin 1B receptor agonists Intranasal
Atogepant AbbVie Pre-registration Calcitonin Gene-Related Peptide Antagonists Orally
LY-3451838 Eli Lilly and Company Phase II Pituitary adenylate cyclase-activating polypeptide receptor antagonists Intravenously
ALLOD 2 Allodynic therapeutics Phase II / III Cyclooxygenase-2 inhibitors Orally
TRV-250 Trevena Phase II Opioid Delta Receptor Agonists Subcutaneous
Prabotulinum toxin A. AEON Biopharma® Phase II Acetylcholine inhibitors Intramuscular
HTL 0022562 Sosei Heptares Phase I. Calcitonin Gene-Related Peptide Antagonists Subcutaneous
UB 313 Vaxxinity Preclinical Calcitonin Gene-Related Peptide Receptor Antagonists N / A

Request a sample to find out more @ Migraine Pipeline Analysis, Key Companies, and Futuristic Trends

Therapeutic evaluation of migraines

The Migraine Pipeline Report provides complete insights into active migraine therapies broken down by stage, product type, route of administration, molecule type, target, and mechanism of action.

By product type

According to stage

  • discovery
  • Preclinical
  • IND
  • Phase I.
  • Phase II
  • Phase III
  • Pre-registration

According to the type of molecule

  • Vaccinations
  • Monoclonal antibody
  • Peptides
  • polymer
  • Small molecule

According to the administrative route

  • Intramuscular
  • Intranasal
  • Orally
  • Subcutaneous
  • Intravenously

According to the mechanism of action

  • Calcitonin Gene-Related Peptide Receptor Antagonists
  • Serotonin 1B receptor agonists
  • Pituitary adenylate cyclase-activating polypeptide receptor antagonists
  • Cyclooxygenase-2 inhibitors
  • Opioid Delta Receptor Agonists
  • Acetylcholine inhibitors

According to goals

  • Calcitonin gene-related peptide receptor
  • Serotonin 1B receptor
  • Pituitary adenylate cyclase-activating polypeptide receptor
  • Cyclooxygenase 2
  • Opioid Delta Receptor
  • Acetylcholine

Contact our manager for Informative business decisions, in / out licensing services, drug portfolio management and advisory solutions

scope Migraine pipeline report

C.excess: Global
Key characters: Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, AbbVie, Eli Lilly and Company, Allodynic Therapeutics, Trevena, AEON Biopharma, Sosei Heptares, Vaxxinity, Pulmatrix, Pear Therapeutics, BetterLife Pharma and others.
Major Migraine Pipeline Therapies: Zavegepant, STS-101, Atogepant, LY-3451838, ALLOD 2, TRV-250, Prabotulinumtoxin A, HTL 0022562, UB 313, PUR-3100, TD 0148A and others.

Reach @ Migraine Pipeline: Novel Therapies and New Technologies

table of contents

1 Introduction to the report
2 Overview of migraine diseases
3 Migraine pipeline outlook
4th Comparative analysis
5 Migraine therapeutics in the clinical stage
6th Late-stage migraine products (phase III)
7th Mid-stage migraine medication (phase II)
8th Migraine products in the early stages (phase I)
9 Migraine therapeutics in the non-clinical stage
10 Products for the preclinical and detection phase of migraines
11 Migraines – DelveInsight’s Analytical Perspective
12th In-depth business evaluation
13th Migraine cooperation offers
14th Analysis of the migraine therapy pipeline
fifteen Inactive Migraine Pipeline Products
16 Key Migraine Companies
17th Migraines – unmet needs
18th Market drivers and barriers to migraines
19th Migraines – Future Prospects and Conclusions
20th attachment
21 Reporting methodology
22nd Consulting services
23 Disclaimer of liability
24 About DelveInsight

To learn more about what’s covered, visit @ New therapies, treatments, and ongoing clinical trials for migraines

Related reports

Migraine market
DelveInsights “Migraines – Market Insights, Epidemiology, and Market Forecast – 2030” Report.

Cerebral Hemorrhage Market
DelveInsights “Cerebral Hemorrhage – Market Insights, Epidemiology, and Market Forecast 2030” Report.

Charcot-Marie Dental Diseases Market
DelveInsights’Charcot-Marie-Tooth Disease – Market Insights, Epidemiology, and Market Forecast –2030 ‘ Report.

Chronic Pain Market
DelveInsights “Chronic Pain – Market Insights, Epidemiology, and Market Forecast – 2030” Report.

Chronic Traumatic Encephalopathy Market
DelveInsights “Chronic Traumatic Encephalopathy (CTE) – Market Insights, Epidemiology, and Market Forecast-2030” Report.

Cluster Headache Market
DelveInsights’Cluster Headache Market Insights, Epidemiology, and Market Forecast – 2030‘ Report

Browse blog posts
Migraine market
Neurological Disorders and Recent Breakthroughs in the Market

Above DelveInsight

DelveInsight is a leading management consulting and research firm focused solely on the life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all health and pharmaceutical market research reports through our subscription-based platform PharmDelve.

You can find more insights under Pharma, healthcare and biotechnology news